This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
In over 214,000 matched patients with type 2 diabetes, GLP-1 receptor agonist users had 19% lower risk of new neurodegenerative disease compared to DPP-4 inhibitor users over 4 years. The association held for dementia and Alzheimer's but not Parkinson's disease.
Why it matters
Type 2 diabetes significantly increases dementia risk. This large real-world study adds to growing evidence that GLP-1 drugs may protect the brain, supporting the case for dedicated clinical trials.
The numbers in context
214,442 matched individuals. Mean follow-up 4.0 years. Composite neurodegeneration HR 0.81 (95% CI 0.77-0.86). Dementia HR 0.76. Alzheimer's HR 0.77. Vascular dementia HR 0.75. Parkinson's HR 1.04 (not significant). Semaglutide HR 0.75, liraglutide HR 0.77, dulaglutide HR 0.82.
How the study worked
Retrospective cohort using TriNetX platform (170M+ records). Propensity-score matched 1:1. GLP-1RA vs DPP-4i initiators (2010-2021). Cox regression for composite and individual neurodegenerative outcomes over up to 5 years. Separate analysis vs basal insulin.
Who was studied
Adults with type 2 diabetes without prior neurodegeneration, mean age 58.6 years, 51% women
What this study cannot tell us
Observational design cannot prove causation. Potential residual confounding despite matching. Database study may have diagnostic coding inaccuracies. Parkinson's showed no benefit.
Read the original research
Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.
Cardiovascular diabetology, 24(1), 426
Citation
Schechter, Meir; Fishkin, Alisa; Mosenzon, Ofri; Sehtman-Shachar, Dvora R; Cukierman-Yaffe, Tali; Leibowitz, Gil; Aharon-Hananel, Genya. (2025). Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.. Cardiovascular diabetology, 24(1), 426. https://doi.org/10.1186/s12933-025-02962-8